ADAG

Adagene Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$2

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %6.6 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %23.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Website

Analysis (Turkish): ADAG Hissesi Caiz mi, Helal mi? Adagene Inc. Katılım Analizi